Company expects to supply Bronchitol to approximately 40,000 patients per year.
Pharmaxis says that it intends to expand its manufacturing capacity with a new facility in Sydney. The company expects to complete construction in the fourth quarter of 2008. Once ready, Pharmaxis may lease the 7,000-square-meter manufacturing and research plant for a term of 15 years with two five-year renewal options.
The purpose-built facility, according to the company, will include an expanded manufacturing plant with initial capacity sufficient to supply Bronchitol to approximately 40,000 patients per year. Pharmaxis is developing Bronchitol for the treatment of diseases including cystic fibrosis, bronchiectasis, and chronic bronchitis.
Additionally, the site will house the commercial, clinical, and administration functions of the company as well as the drug discovery group, which is currently located at North Ryde.
Construction of the essential manufacturing equipment reportedly began in Denmark earlier this year. The premises will provide further opportunities to expand initial capacity in a modular fashion, notes Pharmaxis.